|Bid||0.1950 x 102397000|
|Ask||0.2000 x 716752400|
|Day's range||0.1800 - 0.2050|
|52-week range||0.1300 - 0.6250|
|Beta (5Y monthly)||2.26|
|PE ratio (TTM)||N/A|
|Earnings date||28 Aug 2022 - 01 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.55|
SYDNEY & LOS ANGELES, May 17, 2022--Imugene Limited and City of Hope's first patient was dosed in a clinical trial evaluating the safety of new cancer-killing virus CF33-hNIS VAXINIA.
New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomasnextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and s
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Imugene ( ASX:IMU...